MX2017014140A - Proteinas agonistas receptoras cd40 de cadena simple. - Google Patents

Proteinas agonistas receptoras cd40 de cadena simple.

Info

Publication number
MX2017014140A
MX2017014140A MX2017014140A MX2017014140A MX2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A MX 2017014140 A MX2017014140 A MX 2017014140A
Authority
MX
Mexico
Prior art keywords
receptor agonist
agonist proteins
chain
proteins
cd40l
Prior art date
Application number
MX2017014140A
Other languages
English (en)
Other versions
MX379136B (es
Inventor
Hill Oliver
Gieffers Christian
Thiemann Meinolf
Schnyder Tim
Original Assignee
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Ag filed Critical Apogenix Ag
Publication of MX2017014140A publication Critical patent/MX2017014140A/es
Publication of MX379136B publication Critical patent/MX379136B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Se proporcionan en la presente proteínas agonistas receptoras CD40, ácidos nucleicos que codifican para las mismas, y métodos para tratar a un sujeto que presenta una enfermedad o trastorno asociado con CD40L. Las proteínas agonistas receptoras CD40 proporcionadas en la presente comprenden tres dominios solubles CD40L y un fragmento Fc. Las proteínas agonistas receptoras CD40 son sustancialmente no agregantes y adecuadas para aplicaciones terapéuticas, de diagnóstico y/o de investigación.
MX2017014140A 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena sencilla. MX379136B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156813P 2015-05-04 2015-05-04
PCT/EP2016/059983 WO2016177771A1 (en) 2015-05-04 2016-05-04 Single-chain cd40-receptor agonist proteins

Publications (2)

Publication Number Publication Date
MX2017014140A true MX2017014140A (es) 2018-03-15
MX379136B MX379136B (es) 2025-03-10

Family

ID=56087236

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014140A MX379136B (es) 2015-05-04 2016-05-04 Proteinas agonistas receptoras cd40 de cadena sencilla.

Country Status (12)

Country Link
US (2) US10793616B2 (es)
EP (1) EP3292143B1 (es)
JP (1) JP6738831B2 (es)
KR (1) KR20170138585A (es)
CN (1) CN107709355B (es)
AU (1) AU2016257000B2 (es)
BR (1) BR112017023646A2 (es)
CA (1) CA2984350A1 (es)
ES (1) ES2754432T3 (es)
MX (1) MX379136B (es)
RU (1) RU2745801C2 (es)
WO (1) WO2016177771A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR108468A1 (es) 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
CN112512572B (zh) 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7626698B2 (ja) * 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
CN112996818B (zh) 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
EP3947454A1 (en) * 2019-03-27 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
WO2020207470A1 (zh) 2019-04-10 2020-10-15 南开大学 抗cd40抗体及其用途
CN110760541B (zh) * 2019-10-31 2022-03-29 中国农业科学院兰州兽医研究所 用中国仓鼠卵巢细胞表达外源蛋白时信号肽的选择方法及应用
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN116096733A (zh) 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
WO2009060159A1 (en) * 2007-11-08 2009-05-14 Medigene Limited Mutated ilt molecules
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
DK2604693T3 (en) 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
JP6200437B2 (ja) * 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
US10533054B2 (en) * 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
EP3010547B1 (en) * 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
NO2776305T3 (es) 2014-04-23 2018-01-27

Also Published As

Publication number Publication date
WO2016177771A1 (en) 2016-11-10
CN107709355B (zh) 2021-09-14
KR20170138585A (ko) 2017-12-15
JP2018515072A (ja) 2018-06-14
US20210032309A1 (en) 2021-02-04
MX379136B (es) 2025-03-10
AU2016257000B2 (en) 2020-05-14
RU2745801C2 (ru) 2021-04-01
ES2754432T3 (es) 2020-04-17
CA2984350A1 (en) 2016-11-10
RU2017141727A3 (es) 2019-11-05
CN107709355A (zh) 2018-02-16
RU2017141727A (ru) 2019-06-04
US20180066036A1 (en) 2018-03-08
AU2016257000A1 (en) 2017-11-23
JP6738831B2 (ja) 2020-08-12
BR112017023646A2 (pt) 2018-07-17
WO2016177771A9 (en) 2017-06-29
EP3292143A1 (en) 2018-03-14
US10793616B2 (en) 2020-10-06
EP3292143B1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
UA118286C2 (uk) Білок агоніст рецептора trail
LT3724891T (lt) Vaistų injekcijos ir ligų valdymo sistemos, įrenginiai ir būdai
EP3506312C0 (en) INTERACTIVE SURGICAL SYSTEMS WITH ENCRYPTED COMMUNICATION CAPABILITIES
MX2020000960A (es) Anticuerpos anti-tigit.
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
HK1258726A1 (zh) 嵌合抗原受体(car)t细胞作为获得自体免疫和同种免疫的治疗性干预
EP3266382A4 (en) Puncture needle for endoscopes, and biopsy system
EP3296395A4 (en) Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
BR112016018907A2 (pt) produto reticulado, método para sua produção e o uso deste, e copolímero de etileno.
BR112017014598A2 (pt) métodos e usos para hidrólise de queratina
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP3100752A4 (en) Puncture needle for medical use, and method for manufacturing puncture needle
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
EP3279217A4 (en) Streptococcus pneumoniae protein antigen, and preparation method and use thereof
EP3366210A4 (en) Medical imaging device and magnetic resonance imaging device, and control method therefor
HK1244534A1 (zh) 重组疏螺旋体蛋白及其使用方法
EP3130369A4 (en) Drug injection device, medical support system employing same, and medical support method
EP3111868A4 (en) Medical device, medical system, and mode transition method for medical device
EP3313526A4 (en) B1SP FUSION PROTEIN THERAPEUTICS, METHOD AND USES
IL265195A (en) Protein biomarkers for diseases associated with the contact activation system
BR112018071108A2 (pt) antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos
EP3675766A4 (en) BEDSIDE STEREOTACTIC ULTRASONIC GUIDANCE DEVICE, SYSTEM AND METHOD